Location History:
- Seattle, WA (US) (1999)
- Princeton, NJ (US) (2002)
- Lawrenceville, NJ (US) (2006 - 2007)
- Gaithersburg, MD (US) (2013 - 2018)
- Rockville, MD (US) (2007 - 2019)
Company Filing History:
6 out of 3,684 
5 out of 541 
2 out of 2,009 
Years Active: 1999-2019
Title: Michael A Bowen: Innovator in Antibody Technology
Introduction
Michael A Bowen is a prominent inventor based in Lawrenceville, NJ (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies and recombinant polypeptides. With a total of 12 patents to his name, Bowen's work has had a substantial impact on medical research and therapeutic applications.
Latest Patents
Among his latest patents is the invention titled "Stabilized angiopoietin-2 antibodies and uses thereof." This patent describes stabilized antibodies directed to Angiopoietin-2, along with the nucleic acid and amino acid sequences, hybridomas, or other cell lines for expressing such antibodies. Another notable patent is focused on "Recombinant polypeptide production," which discloses a method for producing a recombinant polypeptide in a mammalian cell culture with modified microRNA activity levels. This innovative approach allows for the adjustment of microRNA activity levels, enhancing the efficiency of polypeptide production.
Career Highlights
Michael A Bowen has worked with leading companies in the biotechnology sector, including Bristol-Myers Squibb Company and MedImmune Limited. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research in antibody technology.
Collaborations
Throughout his career, Bowen has collaborated with notable professionals in the field, including Alejandro A Aruffo and Ralph Raymond Minter. These collaborations have further enriched his research and development efforts.
Conclusion
Michael A Bowen's innovative work in antibody technology and recombinant polypeptide production has positioned him as a key figure in biotechnology. His contributions continue to influence the development of new therapeutic solutions.